Dr. Samuel J. Yamshon, MD

Dr. Yamshon practices at NYU Langone - Tisch Hospital in New York, New York.

Dr. Yamshon's NPI, 1174914543, was assigned on February 6, 2015. Dr. Yamshon graduated from UC Davis School of Medicine in 2016. Dr. Yamshon holds New York license 300013.

Dr. Yamshon's primary practice is NYU Langone - Tisch Hospital, at 550 1st Ave, New York, NY 10016 in New York County. The practice phone is (212) 263-1481.

Dr. Yamshon's primary practice is NYU Langone - Tisch Hospital in New York, New York. Dr. Yamshon is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Yamshon to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yamshon practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Yamshon's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Yamshon is board certified in hematology by the American Board of Internal Medicine. Dr. Yamshon is licensed in New York.

Dmand AI lists chronic anemia, immune deficiency disease, lymphoma and neutropenia among the conditions Dr. Yamshon treats.

CMS data shows 691 Medicare services from Dr. Yamshon across 6 procedure codes in 2024, for 114 Medicare patients. Medicare paid $55,886 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 114 Medicare patients who saw Dr. Yamshon in 2024. The largest group is 65 to 74, with 58 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 3.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yamshon's median patient age at 67, with 45% women.

In 2024, Dr. Yamshon wrote 78 Medicare Part D claims for 25 patients. 74% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $766 in total drug cost. In 2021, CMS named 41 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Yamshon for performance year 2024, reported through an alternative payment model (APM). Dr. Yamshon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yamshon as offering telehealth.

Dmand AI links 26 papers to Dr. Yamshon, published from 2018 to 2025. 2025 was the busiest year, with 7. The most frequent topics are Immunotherapy, Adoptive, Antineoplastic Combined Chemotherapy Protocols and Receptors, Chimeric Antigen. Dr. Yamshon has published most often in Blood Adv. Dr. Yamshon's most frequent co-authors are Peter Martin, MD, Mohammad S. Alhomoud and Jia Ruan, MD, PhD.

CMS Open Payments shows 32 general payments to Dr. Yamshon from 10 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 92% of the total. Gilead Sciences, Inc. paid the most, $9,601. It also lists 1 research payment totaling $159 in 2024.

Dr. Yamshon graduated from UC Davis School of Medicine in 2016. Dr. Yamshon is a member of ACP.

Dr. Yamshon is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.